In short
Boston Scientific Corporation (BSX) has revenue up 19.9% to $20.1B and net income up 56.7% to $2.9B year on year. Its net margin is 14.4% and gross margin 69.0%, and it trades at 19.3× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this
Compare: BSX vs MDT · ABT vs BSX · BSX vs SYK · BSX vs ZBH
Valuation
HealthcareLive · Yahoo FinancePrice
$41.98
$60.8B
13.0x
52-Week Range
Decision Context
Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — BSX
Inflationary BoomStrengths
Net Income: $2.9B (+56.7% YoY) — Profit grew 57% — the company kept more of each dollar earned.
EPS (Diluted): $1.94 (+55.2% YoY) — Earnings per share rose 55% — each share earned more.
Operating Cash Flow: $4.5B (+32.0% YoY) — Operating cash flow grew 32% — the business generated more cash from day-to-day operations.
Gross Profit: $13.9B (+20.6% YoY) — Gross profit rose 21% — the spread between revenue and direct costs improved.
Revenue: $20.1B (+19.9% YoY) — Revenue grew 20% — the company sold more goods or services than the prior year.
Weaknesses
No material weaknesses flagged.
Opportunities
No clear opportunities identified at this time.
Threats
Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.
Year-over-Year Changes
Net Income
$2.9B
was $1.8B
Profit grew 57% — the company kept more of each dollar earned.
EPS (Diluted)
$1.94
was $1.25
Earnings per share rose 55% — each share earned more.
Operating Cash Flow
$4.5B
was $3.4B
Operating cash flow grew 32% — the business generated more cash from day-to-day operations.
Gross Profit
$13.9B
was $11.5B
Gross profit rose 21% — the spread between revenue and direct costs improved.
Revenue
$20.1B
was $16.7B
Revenue grew 20% — the company sold more goods or services than the prior year.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.
Technical Signals
Daily closes · 1-year dataBoston Scientific Corporation: common questions
Is Boston Scientific Corporation profitable?
Yes. Boston Scientific Corporation made a net profit of $2.9B in its latest fiscal year (fiscal 2025), a net margin of 14.4%.
Is Boston Scientific Corporation's revenue growing?
Yes. Revenue grew 19.9% year on year, to $20.1B.
What is Boston Scientific Corporation's P/E ratio?
Boston Scientific Corporation trades at 17.7× its trailing twelve-month earnings. In other words, the share price is about 18 times the profit per share the company earned over the past year.
Does Boston Scientific Corporation pay a dividend?
No dividend is currently expected from Boston Scientific Corporation, according to the latest market data.
What are the main risks for Boston Scientific Corporation?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.
Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — BSX
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade BSX
Links open broker research pages. Not an endorsement or recommendation.
Research Boston Scientific Corporation
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.